Skip to main content Skip to main navigation menu Skip to site footer

Correlation between serum interleukin-6 levels and the severity of Enlist ENL Severity Scale (EESS) in Erythema Nodosum Leprosum (ENL) patients

  • Nahrisyah ,
  • Ramona Dumasari Lubis ,
  • Remenda Siregar ,


Introduction: Leprosy is a chronic infection caused by Mycobacterium leprae (M. Leprae) which no biological examination can yet be appointed as an early marker. This research is aimed to analyze the correlation between serum IL-6 levels and the severity of the ENLIST ENL Severity Scale (EESS) in ENL.

Methods: A cross-sectional study was conducted on all leprosy patients with ENL who sought treatment at the Dermatology and Venereology Polyclinic, North Sumatra University Hospital, dr. Pirngadi General Hospital, and H. Adam Malik General Hospital Medan. ENL patients who were uncooperative, with infectious, autoimmune, malignant diseases, or who were pregnant or breastfeeding were excluded. Data processing was carried out with the help of statistical software with a significance value <0.05.

Results: A total of 40 ENL patients were studied. The mean age of the patients was 33.10±12.23 years, male (70%), high school (75%), and not working (95%). The degree of severity based on mild EESS was more dominant than severe, namely 57.5% vs 42.5%, respectively. The median IL6 level was 64.65±34.06 in ENL patients and was higher in severe compared with mild EESS, namely 105.18±24.14 versus 50.08±16.84, respectively (p=0.103, p=0.167, respectively). There was a very strong and significant positive correlation between serum IL6 levels and EESS (r: 0.813 and p<0.05).

Conclusion: There was a correlation between serum IL6 levels and EESS. Further study is needed in measuring serum IL6 levels to detect early severity of ENL.


  1. Salgado CG, de Brito AC, Salgado UI, Spencer JS. Leprosy. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, Orringer JS, editors. Fitzpatricks’ Dermatology in General Medicine. 9th ed. New York: McGraw Hill Companies; 2019. p.2892–924.
  2. Lastória JC, de Abreu MAMM. Leprosy: review of the epidemiological, clinical, and etiopathogenic aspects - Part 1. An Bras Dermatol. 2014;89(2):205–18.
  3. World Health Organization. Global Health Observation (data): Leprosy (Hansen’s Disease). 2020. Available from: (cited 2021 Sep 17th).
  4. Kementerian Kesehatan Republik Indonesia. Profil Kesehatan Indonesia Tahun 2019. 2020. Available from: (cited 2021 Sep 17th).
  5. Bhat RM, Vaidya TP. What is new in the pathogenesis and management of erythema nodosum leprosum. Indian Dermatology Online Journal. 2020;11(4):482–92.
  6. Vilani-Moreno FR, Brito-de-Souza VN, Silva SUR, Barbosa AS, Sartori BG, Campanelli AP, et al. Increased serum levels of interleukin-6 in erythema nodosum leprosum suggest its use as a biomarker. Indian J Dermatol Venereol Leprol 2021;87:190–8.
  7. Renault CA, Ernst JD. 252 - Mycobacterium leprae (Leprosy). In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases (Eighth Edition) [Internet]. Philadelphia: W.B. Saunders; 2015 [cited 2021 Feb 28]. p. 2819–2831.e2. Available from:
  8. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev. 2006;19:338–81.
  9. Walker SL, Balagon M, Darlong J, Doni SN, Hagge DA, Halwai V, et al. ENLIST 1: An international multi-centre cross-sectional study of the clinical features of erythema nodosum leprosum. PLoS Negl Trop Dis. 2015;9(9):1–14.
  10. Baima de Melo C, Silva de Sá BD, Aníbal Carvalho Costa F, Nunes Sarno E. Epidemiological profile and severity of erythema nodosum leprosum in Brazil: a cross-sectional study. Int J Dermatol. 2020;59(7):856-61.
  11. Chen X, Zha S, Shui TJ. Presenting symptoms of leprosy at diagnosis: Clinical evidence from a cross-sectional, population-based study. PLoS Negl Trop Dis. 2021;15(11):e0009913.
  12. Cuellar-Barboza A, Cardenas-de la Garza JA, García-Lozano JA, Vera-Pineda R, Cruz-Gomez LG, Irabien-Zuniga M, et al. Leprosy reactions in North-East Mexico: epidemiology and risk factors for chronic erythema nodosum leprosum. J Eur Acad Dermatol Venereol. 2020;34(5):e228–9.
  13. Walker SL, Sales AM, Butlin CR, Shah M, Maghanoy A, Lambert SM, et al. A leprosy clinical severity scale for erythema nodosum leprosum: An international, multicentre validation study of the ENLIST ENL Severity Scale. PLoS Negl Trop Dis. 2017;11(7):1–14.
  14. Fischer M. Leprosy - an overview of clinical features, diagnosis, and treatment. J Dtsch Dermatol Ges. 2017;15(8):801–27.
  15. Nambiar PH, Katikaneni M, Al Nahlawi B, Hayat SQ. Leprosy after interleukin 6 inhibitor therapy in a patient with rheumatoid arthritis. Lancet Infect Dis. 2019;19(7):787.
  16. Cassirer-Costa F, Medeiros NI, Chaves AT, Lyon S, Coelho-Dos-Reis JGA, Ribeiro-Junior AF, et al. Cytokines as biomarkers to monitoring the impact of multidrug therapy in immune response of leprosy patients. Cytokine. 2017;97:42–8.
  17. Stefani MM, Guerra JG, Sousa AL, Costa MB, Oliveira ML, Martelli CT, et al. Potential plasma markers of Type 1 and Type 2 leprosy reactions: A preliminary report. BMC Infect Dis. 2009;9:75.
  18. Iyer A, Hatta M, Usman R, Luiten S, Oskam L, Faber W, et al. Serum levels of interferon gamma, tumour necrosis factor alpha, soluble interleukin 6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions. Clin Exp Immunol. 2007;150:210–6.
  19. Sales Marques C, Cardoso CC, Alvarado Arnez LE, Illaramendi X, Sales AM, Hacker MA, et al. Genetic polymorphisms of the IL-6 and NOD2 genes are risk factor for inflamatory reactions in leprosy. PLoS Ngel Trop Dis. 2017;11:e0005754.

How to Cite

Nahrisyah, Lubis, R. D., & Siregar, R. (2024). Correlation between serum interleukin-6 levels and the severity of Enlist ENL Severity Scale (EESS) in Erythema Nodosum Leprosum (ENL) patients. Bali Medical Journal, 13(1), 373–376.




Search Panel